{"id":"https://openalex.org/W7225417820","doi":"https://doi.org/10.3389/fonc.2026.2004627","title":"Case Report: Durable response to tislelizumab monotherapy in microsatellite-stable, BRAF V600E-mutant right-sided colon cancer with extremely high PD-L1 expression","display_name":"Case Report: Durable response to tislelizumab monotherapy in microsatellite-stable, BRAF V600E-mutant right-sided colon cancer with extremely high PD-L1 expression","publication_year":2026,"publication_date":"2026-11-06","ids":{"openalex":"https://openalex.org/W7225417820","doi":"https://doi.org/10.3389/fonc.2026.2004627"},"language":"en","primary_location":{"id":"doi:10.3389/fonc.2026.2004627","doi":"https://doi.org/10.3389/fonc.2026.2004627","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.2004627","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.2004627/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.2004627/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5161081631","display_name":"Chen Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210163399","display_name":"Shandong First Medical University","ror":"https://ror.org/05jb9pq57","country_code":"CN","type":"education","lineage":["https://openalex.org/I4210163399"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Chen Li","raw_affiliation_strings":["Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University","institution_ids":["https://openalex.org/I4210163399"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045026848","display_name":"MingYan Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210163399","display_name":"Shandong First Medical University","ror":"https://ror.org/05jb9pq57","country_code":"CN","type":"education","lineage":["https://openalex.org/I4210163399"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Mingyan Li","raw_affiliation_strings":["Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University","institution_ids":["https://openalex.org/I4210163399"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159444841","display_name":"Simin Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210163399","display_name":"Shandong First Medical University","ror":"https://ror.org/05jb9pq57","country_code":"CN","type":"education","lineage":["https://openalex.org/I4210163399"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Simin Wang","raw_affiliation_strings":["Department of Pathology, The Second Affiliated Hospital of Shandong First Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, The Second Affiliated Hospital of Shandong First Medical University","institution_ids":["https://openalex.org/I4210163399"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161043522","display_name":"Mingxin Xu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210163399","display_name":"Shandong First Medical University","ror":"https://ror.org/05jb9pq57","country_code":"CN","type":"education","lineage":["https://openalex.org/I4210163399"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Mingxin Xu","raw_affiliation_strings":["Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University","institution_ids":["https://openalex.org/I4210163399"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5161049225","display_name":"Haiyan Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210163399","display_name":"Shandong First Medical University","ror":"https://ror.org/05jb9pq57","country_code":"CN","type":"education","lineage":["https://openalex.org/I4210163399"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Haiyan Liu","raw_affiliation_strings":["Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University","institution_ids":["https://openalex.org/I4210163399"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5161049225"],"corresponding_institution_ids":["https://openalex.org/I4210163399"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5214999914169312,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5214999914169312,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.44699999690055847,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11369","display_name":"Genetic factors in colorectal cancer","score":0.01759999990463257,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tislelizumab","display_name":"tislelizumab","score":0.9789999723434448},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.9440000057220459},{"id":"https://openalex.org/keywords/right-sided-colon-cancer","display_name":"right-sided colon cancer","score":0.8610000014305115},{"id":"https://openalex.org/keywords/microsatellite-stability","display_name":"microsatellite stable","score":0.7910000085830688},{"id":"https://openalex.org/keywords/proficient-mismatch-repair","display_name":"proficient mismatch repair","score":0.9399999976158142},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.8650000095367432},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7620000243186951},{"id":"https://openalex.org/keywords/raltitrexed","display_name":"raltitrexed","score":0.9100000262260437},{"id":"https://openalex.org/keywords/liver-abscess","display_name":"liver abscess","score":0.5730000138282776},{"id":"https://openalex.org/keywords/intestinal-obstruction","display_name":"intestinal obstruction","score":0.6510000228881836},{"id":"https://openalex.org/keywords/durable-response","display_name":"durable response","score":0.5609999895095825}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8881000280380249},{"id":"https://openalex.org/C2779268555","wikidata":"https://www.wikidata.org/wiki/Q15304877","display_name":"Raltitrexed","level":5,"score":0.6837000250816345},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.6561999917030334},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6065999865531921},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5684999823570251},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.5214999914169312},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.44190001487731934},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.423799991607666},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.39739999175071716},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.39250001311302185},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.3885999917984009},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.3855000138282776},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3666999936103821},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.3467999994754791},{"id":"https://openalex.org/C2993158029","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colon adenocarcinoma","level":4,"score":0.32919999957084656},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3244999945163727},{"id":"https://openalex.org/C60748783","wikidata":"https://www.wikidata.org/wiki/Q2984243","display_name":"DNA mismatch repair","level":4,"score":0.30979999899864197},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.29010000824928284},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.2892000079154968},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.28380000591278076},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2825999855995178},{"id":"https://openalex.org/C2776470698","wikidata":"https://www.wikidata.org/wiki/Q21851559","display_name":"V600E","level":4,"score":0.2806999981403351},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.27410000562667847},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.25760000944137573}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3389/fonc.2026.2004627","doi":"https://doi.org/10.3389/fonc.2026.2004627","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.2004627","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.2004627/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:ef9bb2d0573a4fa3b2654fcfac0a9df5","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/ef9bb2d0573a4fa3b2654fcfac0a9df5","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Oncology, Vol 16 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fonc.2026.2004627","doi":"https://doi.org/10.3389/fonc.2026.2004627","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.2004627","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.2004627/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225417820.pdf","grobid_xml":"https://content.openalex.org/works/W7225417820.grobid-xml"},"referenced_works_count":15,"referenced_works":["https://openalex.org/W2091103707","https://openalex.org/W2129998117","https://openalex.org/W3110528877","https://openalex.org/W3148370335","https://openalex.org/W3157885804","https://openalex.org/W3173109309","https://openalex.org/W3185030463","https://openalex.org/W4292482598","https://openalex.org/W4391671392","https://openalex.org/W4395453673","https://openalex.org/W4399559384","https://openalex.org/W4413788974","https://openalex.org/W7125370672","https://openalex.org/W7134037278","https://openalex.org/W7162574616"],"related_works":["https://openalex.org/W7220676951","https://openalex.org/W7160520893","https://openalex.org/W4323665960","https://openalex.org/W7154937465","https://openalex.org/W3211572346","https://openalex.org/W4412431003","https://openalex.org/W4415015018","https://openalex.org/W4389066404","https://openalex.org/W2463081617","https://openalex.org/W7133316316"],"abstract_inverted_index":{"Colorectal":[0],"cancer":[1],"with":[2,19,159,212,233,292],"proficient":[3],"mismatch":[4,265],"repair":[5,266],"(pMMR)/microsatellite":[6],"stable":[7],"(MSS)":[8],"status":[9,129],"is":[10,204,273],"generally":[11],"intrinsically":[12],"resistant":[13],"to":[14,149],"immune":[15],"checkpoint":[16],"inhibitors;":[17],"tumors":[18],"concomitant":[20],"BRAF":[21,64,217,251],"V600E":[22,65,218],"mutations":[23],"are":[24],"highly":[25],"aggressive,":[26],"and":[27,30,67,96,101,139,153,226,295],"conventional":[28],"chemotherapy":[29,145],"targeted":[31],"therapies":[32],"have":[33],"limited":[34,296],"efficacy,":[35],"resulting":[36],"in":[37,45,181,276],"a":[38,51,63,102,135,163,177,210,216,231,234,284],"lack":[39],"of":[40,53,88,137,174,200,209,256,264],"effective":[41],"personalized":[42,286],"treatment":[43,287],"options":[44],"clinical":[46],"practice.":[47],"This":[48,246],"report":[49],"describes":[50],"case":[52,208,247],"locally":[54],"advanced":[55],"right-sided":[56],"colon":[57],"adenocarcinoma":[58,214],"that":[59,249],"was":[60,113,146,194],"pMMR/MSS,":[61],"harbored":[62],"mutation,":[66,219],"exhibited":[68],"high":[69,108,223,270],"programmed":[70,238],"death-ligand":[71],"1":[72,242],"(PD-L1)":[73],"expression":[74,225,258,272],"(tumor":[75],"proportion":[76],"score":[77],"[TPS]":[78],">":[79],"95%).":[80],"The":[81],"patient":[82,155,211],"developed":[83,99],"intestinal":[84],"obstruction":[85],"after":[86],"failure":[87],"first-line":[89],"conversion":[90],"therapy.":[91],"After":[92,123,171],"undergoing":[93],"palliative":[94],"gastrojejunostomy":[95],"cecostomy,":[97],"she":[98],"gastroparesis":[100],"liver":[103,151],"abscess.":[104],"Given":[105],"the":[106,116,126,154,168,182,189,198,205,277],"extremely":[107,222,269],"PD-L1":[109,224,257,271],"expression,":[110],"tislelizumab":[111,138,160],"monotherapy":[112],"initiated":[114],"before":[115],"patient\u2019s":[117,127],"general":[118],"condition":[119],"had":[120],"fully":[121],"recovered.":[122],"three":[124],"cycles,":[125],"performance":[128],"improved":[130],"significantly.":[131],"She":[132],"then":[133],"received":[134],"combination":[136],"raltitrexed":[140],"for":[141,250,289],"two":[142],"cycles;":[143],"however,":[144],"discontinued":[147],"due":[148],"raltitrexed-induced":[150],"injury,":[152],"continued":[156],"maintenance":[157,175],"therapy":[158],"monotherapy,":[161],"achieving":[162],"partial":[164],"response":[165],"(PR)":[166],"as":[167],"best":[169,199],"outcome.":[170],"nine":[172],"cycles":[173],"therapy,":[176],"new":[178],"mass":[179],"appeared":[180],"right":[183],"adnexal":[184],"region,":[185],"indicating":[186],"disease":[187],"progression;":[188],"overall":[190],"progression-free":[191],"survival":[192],"(PFS)":[193],"14":[195],"months.":[196],"To":[197],"our":[201],"knowledge,":[202],"this":[203],"first":[206],"reported":[207],"colorectal":[213,253],"harboring":[215],"characterized":[220],"by":[221],"pMMR/MSS":[227,278],"status,":[228],"who":[229],"achieved":[230],"PR":[232],"regimen":[235],"centered":[236],"on":[237],"cell":[239],"death":[240],"protein":[241],"(PD-1)":[243],"inhibitor":[244],"monotherapy.":[245],"suggests":[248],"V600E-mutated":[252],"cancer,":[254],"assessment":[255],"levels":[259],"should":[260],"be":[261],"considered":[262],"regardless":[263],"status;":[267],"if":[268],"present,":[274],"even":[275],"phenotype,":[279],"PD-1":[280],"inhibitors":[281],"may":[282],"offer":[283],"potential":[285],"option":[288],"these":[290],"patients":[291],"poor":[293],"prognosis":[294],"therapeutic":[297],"choices.":[298]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-11-07T00:00:00"}